314 results
F-3ASR
EX-4.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
or opinion has read such covenant or condition and the definitions herein relating thereto;
(2) a brief statement as to the nature and scope … such defaults and the nature and status thereof of which they may have knowledge. For the purpose of this Section 1005, such compliance with the terms, conditions
6-K
EX-99.4
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success
6-K
EX-99.2
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise
6-K
EX-99.1
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
investigation plan (PIP) as part of the overall clinical development plan. Submission is currently planned for 2027. Given the integral nature of the project
F-6EF
EX-99
uzvrw w4f
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
EX-99.1
8a68ew2 zu9
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
w2p tbzg9d5w
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.2
9ptxe l2ec3vmj
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.3
7f3jzd4o9szy7q
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
fkk2xb7d0d5618 3gu
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
gs92uyhwuhppo fr
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
us27s1c9q2mqf7
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.2
t32dfjsl 5tem1
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
30zjw
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
tuf91b i9r6sf
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
1pwqehr89azr25nymu
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
iekz9i py7
17 Oct 22
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
1:35pm
6-K
EX-99.1
zrbxe9hfy3k
3 Oct 22
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
11:24am
6-K
EX-99.2
1z6pt7qp73
12 Sep 22
Evolution of the Board of Directors
7:07am